Hormone Therapy to Boost Weight Loss in GLP-1 Users

A new study will show that combining menopause hormone therapy with GLP-1 drugs enhances weight loss results in women.

Updated on Oct. 21, 2026 in Weight Loss

Bold vector editorial illustration showing two stylized vessels with organic and geometric forms, representing the combination of medical therapies. — A new study indicates that combining hormone therapy with GLP-1 weight-loss medications may enhance effectiveness for women aged 45 and older. AI Illustration. Upload story photo >

Live Poll

Would you discuss menopause hormone therapy with your doctor to potentially improve weight loss results?

Research to be presented on October 22, 2026, finds that women using hormone therapy alongside GLP-1 medications see improved weight loss outcomes. The findings highlight a potential synergy between these treatments for women aged 45 and older.

Why it matters

Understanding how hormone therapy interacts with GLP-1 drugs like semaglutide is critical as millions of women utilize these medications for weight management. Preclinical data suggests a possible synergistic effect between estrogen and GLP-1 signaling.

A study of 3,900 women showed that 22% of those combining semaglutide with hormone therapy achieved 20% or more weight loss, compared to 18% of those on semaglutide alone. Additionally, 1 in 5 U.S. women aged 50 to 64 have used GLP-1 medication.

The players

Menopause Society

This is a nonprofit organization dedicated to promoting the health and quality of life of women during menopause and beyond through education and research.

The details

Researchers tracked 2,400 semaglutide users and 1,500 tirzepatide users with an average age of 57 to compare outcomes. Tirzepatide users on hormone therapy demonstrated 6.6% weight loss at three months, compared to 5.9% for those taking the drug alone.

October 22, 2026: The research will be presented at the Menopause Society annual meeting.
Through October 24, 2026: The Menopause Society holds its annual meeting in San Diego.

Health Landscape

The findings presented at the Menopause Society annual meeting mark a significant shift in how researchers evaluate weight management for postmenopausal women. This study suggests that future clinical approaches may increasingly account for hormonal status when prescribing GLP-1 medications.

Women currently using GLP-1 medications may want to discuss the potential impact of hormone therapy on their treatment results with their healthcare provider. These findings could lead to more personalized medication plans for those aged 45 and older.

The takeaway

Patients should consult with their doctors to understand if their current hormone levels might influence the effectiveness of weight loss treatments. Continued research will be essential to provide definitive guidance on combining these specific therapeutic regimens.